Compare Gilead Sciences, Inc. (GILD) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Vanguard Total International Stock Index Fund ETF trades at $84.64 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 3.7× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| GILD | VXUS | |
|---|---|---|
Market Cap | $182.09B | $665.70B |
Volume | 4,960,247 | 4,890,695 |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $88.41 |
52-Week Low | $116.74 | $72.17 |
Typical Hold Time | 111 Days | 55 Days |
Enterprise Value | $205.15B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
VXUS, the Vanguard Total International Stock ETF, is trading at $84.78, down 1.19% on the day, with a bearish technical signal driven by moving averages. The ETF provides diversified exposure to international developed and emerging markets outside the U.S. Recent news highlights its role in portfolio diversification and long-term growth potential, with several financial firms increasing their positions in Q2 2026.
The outlook for VXUS hinges on international market performance relative to the U.S., offering a hedge against domestic downturns. Key risks include currency fluctuations, geopolitical tensions, and the ETF's inability to reclaim foreign tax credits in IRAs. Its low-cost, broad diversification presents a strategic opportunity for long-term investors seeking global equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
